ANIXA BIOSCIENCES INC

Insider buying at Anixa Biosciences (ANXB) shows CEO confidence amid a 21.9% decline; explore the risks and upside of its CAR‑T and vaccine pipeline.

Investors spot insider confidence in Anixa Biosciences (ANXA) as its diagnostic and therapeutic pipeline gains traction, hinting at upside potential amid a competitive oncology market.

Insight: Anixa Biosciences CEO Amit Kumar’s recent insider buying signals confidence in its cancer‑diagnostic platform—watch upcoming clinical milestones for real value.

CEO Kumar Amit’s latest buy of 5,000 Anixa Biosciences shares at $3.46 shows leadership confidence and hints at a strong diagnostic pipeline and potential upside.

Insider buying of Anixa Biosciences shares signals confidence in its breast‑cancer vaccine pipeline and upcoming clinical milestones, hinting at future upside.

Insider buying at Anixa Biosciences shows steady confidence as the company secures Mexican patents, advances breast‑cancer vaccine trials, and plans FDA approval, hinting at long‑term growth.